home | publications


1. Evaluation of ERG Responsive Proteome in Prostate Cancer
Tan S-H, Furusato B, Fang XP, Fang H, Mohamed AA, Griner N, Sood K, Saxena S, Katta S, Young D, Chen Y, Sreenath T, Petrovics G, Dobi A, Sesterhenn IA, Saxena S and Srivastava S.
The Prostate. 2014; 74(1):70-89.

2. Analysis Of The ERG Rearrangement And Protein Expression In The Progression To Castration-Resistant Prostate Cancer
Gsponer JR, Braun M, Scheble VJ, Zellweger T, Rentsch CA, Bachmann A, Perner S, Sesterhenn IA, Srivastava S, Dobi A, Bubendorf L, Ruiz C.
Prostate Cancer and Prostatic Diseases. 2014; 17(2):126-31.

3. NKX3.1 Is A Negative Regulator Of TMPRSS2-ERG Fusions In Prostate Cancer
Thangapazham R, Saenz F, Katta S, Mohamed AA, Tan S-H, Petrovics G, Srivastava S and Dobi A.
BMC Cancer. 2014: Jan 13;14:16.

4. Methylation of PMEPA1, a Negative Regulator of the Androgen Receptor, Underlies its Decreased Expression in Prostate Cancer
Sharad S, Ravindranath L, Haffner MC, Li H, Yan W, Sesterhenn IA, Chen Y, Amina A, Cullen J, Srinivasan S, Dobi A, McLeod DG, Srivastava S, Yegnasubramanian S and Petrovics G.
Epigenetics 2014; Apr 2;9(6). [Epub ahead of print]

5. Long Noncoding RNA-Mediated Activation Of Androgen Receptor In Prostate Cancer
Petrovics G, Srivastava S.
Asian J Androl. 2014 May;16(3):418-9.

6. Elevated Alkaline Phosphatase Velocity Strongly Predicts Overall Survival and the Risk of Bone Metastases in Castrate Resistant Prostate Cancer
Metwalli AR; Rosner,IL ; Cullen, J; Chen Y; Brand, T; Brassell, SA; L'esperance, JO; Porter, C; Sterbis, J, McLeod, DG.
Urologic Oncology: Seminars and Original Investigations. 2014 (in press).

7. Increased Association Of The ERG Oncoprotein Expression In Advanced Stages Of Prostate Cancer In Filipinos
Raymundo EM, Diwa MH, Lapitan MCM, Plaza AB, Sevilleja JE, Srivastava S and Sesterhenn IA.
The Prostate. 2014 [Epub ahead of print].

8. ERG Monoclonal Antibody (ERG-Mab, 9FY) In The Diagnosis And Biological Stratification Of Prostate Cancer: Delineation Of Minimal Epitope, Critical Residues For Binding And Molecular Basis Of Specificity.
Rastogi A, Tan S-H, Banerjee S, Sharad S, Srivastava S, Kagan J, McLeod DG, Srivastava S, Srinivasan A.
Monoclonal Antibodies in Immunodiagnosis and Immunotherapy 2014 (in press).

9. Nanotechnology-Based Approaches for the Development of Diagnostics, Therapeutics and Vaccines
Srinivasan A, Rastogi A, Ayyavoo V, Srivastava S.
Monoclonal Antibodies in Immunodiagnosis and Immunotherapy 2014 (in press).

10. Expression of ERG Oncoprotein in Higher Grade Prostate Cancer in Caucasian American and African American Men
Farrell J, Young D, Chen Y, Degon M, Cullen J, Petrovics G, Rosner I, Kagan J, Srivastava S, McLeod DG, Sesterhenn IA and Srivastava S.
Molecular and Clinical Oncology 2014 (in press).

11. ERG Oncoprotein Expression Status In A Multi-Ethnic Cohort Of Cap Patients From Malaysia
Kelly GM, Kong YH, Tan S-H, Dobi A, Sesterhenn IA, Srivastava S, Pathmanathan R, Tan HM, Cheong SC.
Molecular and Clinical Oncology, 2014 (in press).

12. Legends in Urology: Fathollah Keshvar "Kash" Mostofi, MD. An Interview with Isabell Sesterhenn, MD
Haas G.
Canadian Journal of Urology (21) 3 Jun 2014.